*Guest blog by Pivotal. For more information on the information in this blog post please contact Ms. Natalia Farr - [email protected]. If you would like to submit a guest blog please email [email protected].
Tatiana Dicenzo, Senior Regulatory Associate – Pivotal
Fast-track clinical trial procedures in the EU: turning complexity into opportunity
Despite regulatory harmonization, launching a clinical trial in Europe can still be complex and time-consuming. However, evolving fast-track procedures are changing this landscape.
The EU has taken important steps to make…
Tony Jones, CEO, One NucleusEmail: [email protected]
Overview:
On the eve of both the One Nucleus ON Helix conference and publication by the UK Government of their Life Science Sector Plan: Year One Update report, One Nucleus held a working dinner with sixty guests to discuss ‘Working with CROs and CDMOs to Maximise Biotech Company Value Creation”. The dinners are an opportunity for open sharing of best practice insights between peers and debate around how the sector can collectively drive increased competitiveness and success in operational reality against the backdrop of the UK Life…
Report prepared by PM Life Sciences Consulting | May 2026
OverviewIn July 2025 the UK Government published its Life Sciences Sector Plan as a ten-year industrial strategy for one of the country’s flagship sectors. In it, they set out how Government intends to harness UK science and innovation to drive economic growth, attract investment and improve health outcomes. The Plan positions life sciences as a cornerstone of the wider industrial strategy, with a clear ambition to make the UK Europe’s leading life sciences economy by 2030 and the third globally by 2035. It outlines a package of…
by Philippa Clark, Director of Business Development, One Nucleus
Capital efficiency is one of those topics that seems to come up everywhere at the moment. It’s discussed on panels, debated in investor meetings and frequently raised in networking conversations, yet despite how often we hear the term, I was curious to explore what it really means in practice.
Is it possible to be both lean and ambitious? Does capital efficiency look the same from a founder’s perspective as it does from an investor’s? Also, what lessons can experienced leaders learn from one another when navigating increasingly…
by Alicia Gailliez, Business Development Manager, One Nucleus
The One Nucleus Boston Bootcamp 2026 once again brought together an ambitious cohort of UK life science innovators to immerse themselves in one of the world’s most dynamic biotech ecosystems. The selected winning companies this year were ExpressionEdits, Monument Therapeutics, Profionics and Stick Therapeutics. Joining the winners were those self-funding their participation including Luvida, RNera Bio and Quaisr.
Across three days of expert discussions, networking opportunities, pitching opportunities and peer exchange, there was…
by Philippa Clark, Director of Business Development, One Nucleus
There was a real sense of anticipation in the air as delegates arrived at Chesterford Research Park for BioBeat26. Perhaps it was the excitement of seeing BioBeat return. Perhaps it was the opportunity to reconnect with familiar faces and meet new ones. Perhaps it was the significance of the occasion itself, the beginning of a new chapter as BioBeat became part of the One Nucleus conference portfolio.
Whatever the reason, from the speaker networking lunch through to the…
by Alicia Gailliez, Business Development Manager, One Nucleus
Community drives motivation, which helps to create action.
You can see this reflected in the energy, insights, and calls to action that arise from ON Helix. Long after the day of the event itself, as follow-up discussions continue via the conference app, new connections continue to be built exploring opportunities for collaboration as key takeaway messages emerge.
Advancing innovative medicines to patients requires a community that brings together researchers sharing their knowledge, start-ups meeting potential…
By Tony Jones, CEO, One Nucleus - Email: [email protected]
Triggered by advances in technology, geopolitics, and patient expectations, there is no denying that the dynamic landscape of innovation, investment. and integration in the R&D of innovative medicines is changing at a rate not experienced previously. The consequence of rapid change is always the creation of cohorts of winners and losers. Some are entering the game with no preconceptions of how it should work, some will adapt to the new environment to remain competitive, and some will lose their competitive edge. It has long…
Collaborating and Competing in the Brave New Biotech World
Tony Jones, CEO, One Nucleus, Email: [email protected]
Is it new, another cycle or evolution of the biotech sector?
There have always been many pressures on the biotech industry innovation process. Limitations of existing technologies, sufficient understanding of biology, investment gaps, lack of available lab space to scale, lack of available talent to scale, changing regulations and more. Each of these hurdles has been addressed to a greater or lesser degree in numerous cycles throughout the decades of the…
By Natalie, Marketing Manager, One Nucleus
Are you considering joining 300+ life science professionals meeting at ON Helix 2026 on 9 July, and what are you hoping to get out of it?
Whether you are looking at sponsoring the conference to ensure your brand is visible on the conference communications, exhibiting to showcase your business to delegates, or simply attending to hear the keynote presentations and meet the ecosystem, here are some suggestions to help you make the most of your presence in the run-up to and during the conference.
Commit Early to Maximise Customer Touchpoints…